Annual Shareholders Equity
$100.98 M
-$8.24 M-7.54%
31 December 2023
Summary:
Y-mAbs Therapeutics annual stockholders equity is currently $100.98 million, with the most recent change of -$8.24 million (-7.54%) on 31 December 2023. During the last 3 years, it has fallen by -$4.85 million (-4.58%). YMAB annual shareholders equity is now -49.23% below its all-time high of $198.90 million, reached on 31 December 2019.YMAB Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Shareholders Equity
$92.43 M
-$2.91 M-3.05%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly stockholders equity is currently $92.43 million, with the most recent change of -$2.91 million (-3.05%) on 30 September 2024. Over the past year, it has dropped by -$7.72 million (-7.71%). YMAB quarterly shareholders equity is now -63.35% below its all-time high of $252.22 million, reached on 31 March 2021.YMAB Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Shareholders Equity Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -7.5% | -7.7% |
3 y3 years | -4.6% | -56.2% |
5 y5 years | -28.1% | +7.5% |
YMAB Shareholders Equity High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -43.9% | at low | -56.2% | at low |
5 y | 5 years | -49.2% | at low | -63.4% | +7.5% |
alltime | all time | -49.2% | +737.3% | -63.4% | +41.1% |
Y-mAbs Therapeutics Shareholders Equity History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $92.43 M(-3.0%) |
June 2024 | - | $95.34 M(-3.9%) |
Mar 2024 | - | $99.19 M(-1.8%) |
Dec 2023 | $100.98 M(-7.5%) | $100.98 M(+0.8%) |
Sept 2023 | - | $100.15 M(-4.3%) |
June 2023 | - | $104.68 M(-2.9%) |
Mar 2023 | - | $107.83 M(-1.3%) |
Dec 2022 | $109.22 M(-39.4%) | $109.22 M(+1.2%) |
Sept 2022 | - | $107.90 M(-17.9%) |
June 2022 | - | $131.40 M(-16.6%) |
Mar 2022 | - | $157.47 M(-12.6%) |
Dec 2021 | $180.11 M | $180.11 M(-14.6%) |
Sept 2021 | - | $210.84 M(-10.0%) |
June 2021 | - | $234.32 M(-7.1%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2021 | - | $252.22 M(+138.3%) |
Dec 2020 | $105.84 M(-46.8%) | $105.84 M(-9.2%) |
Sept 2020 | - | $116.51 M(-20.2%) |
June 2020 | - | $146.01 M(-16.7%) |
Mar 2020 | - | $175.33 M(-11.9%) |
Dec 2019 | $198.90 M(+41.5%) | $198.90 M(+131.4%) |
Sept 2019 | - | $85.94 M(-20.7%) |
June 2019 | - | $108.38 M(-13.6%) |
Mar 2019 | - | $125.51 M(-10.7%) |
Dec 2018 | $140.53 M(+71.1%) | $140.53 M(-9.4%) |
Sept 2018 | - | $155.03 M(+136.6%) |
June 2018 | - | $65.52 M(-20.2%) |
Dec 2017 | $82.15 M(+581.1%) | $82.15 M |
Dec 2016 | $12.06 M | - |
FAQ
- What is Y-mAbs Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual shareholders equity year-on-year change?
- What is Y-mAbs Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly shareholders equity year-on-year change?
What is Y-mAbs Therapeutics annual stockholders equity?
The current annual shareholders equity of YMAB is $100.98 M
What is the all time high annual shareholders equity for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual stockholders equity is $198.90 M
What is Y-mAbs Therapeutics annual shareholders equity year-on-year change?
Over the past year, YMAB annual stockholders equity has changed by -$8.24 M (-7.54%)
What is Y-mAbs Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of YMAB is $92.43 M
What is the all time high quarterly shareholders equity for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly stockholders equity is $252.22 M
What is Y-mAbs Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, YMAB quarterly stockholders equity has changed by -$7.72 M (-7.71%)